NCT02955940 2025-12-17An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibIncyte CorporationPhase 2 Active not recruiting10 enrolled
NCT02119676 2018-02-13Study of Ruxolitinib in Colorectal Cancer PatientsIncyte CorporationPhase 2 Terminated396 enrolled 15 charts